Pharmaceuticals, Biotechnology and Life Sciences
The U.S. Food and Drug Administration (FDA) has notified Homology that the clinical hold on its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria (PKU) has been lifted.
Oxford Biomedica plc has appointed Ms. Namrata P Patel to the Board as an Independent Non-Executive Director with immediate effect.
Oxford Biomedica said Wednesday it has joined a Consortium lead by the Jenner Institute, Oxford University, to work on a potential vaccine candidate for COVID-19, called ChAdOx1 nCov-19.
Oxford Biomedica has signed a new Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s company, Juno Therapeutics to use Oxford Biomedica’s LentiVector platform for its application in CAR-T and TCR-T programmes in oncology and other indications.
Multi-disciplinary engineering company WHP has secured the design, construction and project management contract for the development of a new viral vector manufacturing centre for Oxford BioMedica.
The FDA has set Novartis’s Kymriah suspension injection for patients who have relapsed or refractory diffuse large B-cell lymphona (DLBCL)…
Oxford BioMedica, a leading gene and cell therapy group, announces that Stuart Paynter will join Oxford BioMedica as Chief Financial Officer to succeed Tim Watts, who has decided to retire from full time executive roles.
Oxford BioMedica, a gene and cell therapy group, has presented results from a Phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax) and low dose cyclophosphamide (CPM) in patients with advanced colorectal cancer (TaCTiCC).
Oxford BioMedica, a UK-based gene and cell therapy group, has published results from the RetinoStat (OXB-201) Phase I study in patients with advanced wet age-related macular degeneration (AMD) in the journal Human Gene Therapy.
Oxford BioMedica plc, a gene and cell therapy group, has announced that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence for two rare orphan disease indications under Oxford BioMedica’s LentiVector platform technology patents.